首页> 外文OA文献 >Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets

【2h】

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets

机译：可定位的ERBB2突变状态是雌激素受体阳性逆行预后的独立标志，ERBB2未扩增的原代小叶乳腺癌：公共数据集的硅分析中的回顾

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Sasagu Kurozumi; Mansour Alsaleem; Cíntia J. Monteiro; Kartikeya Bhardwaj; Stacey E. P. Joosten; Takaaki Fujii; Ken Shirabe; Andrew R. Green; Ian O. Ellis; Emad A. Rakha; Nigel P. Mongan; David M. Heery; Wilbert Zwart; Steffi Oesterreich; Simon J. Johnston;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets [J] . Sasagu Kurozumi, Mansour Alsaleem, Cíntia J. Monteiro, Breast Cancer Research . 2020,第1期

机译：可定位的ERBB2突变状态是雌激素受体阳性逆行预后的独立标志，ERBB2未扩增的原代小叶乳腺癌：公共数据集的硅分析中的回顾
2. Targetable ERBB2 mutations independently predict an aggressive phenotype in primary, ERBB2 non-amplified, hormone receptor positive lobular breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：可定位的ERBB2突变独立地预测初级，ERBB2未扩增的激素受体阳性小叶乳腺癌的侵袭性表型
3. An application of ERBB2 receptor inhibitors in a rare case of S310F somatic ERBB2 mutation of primary signet-ring cell adenocarcinoma of vagina: A case report and review literature of S310F somatic ERBB2 mutation in breast and gynecologic cancers [J] . June Y. Hou, Jason D. Wright, Vuthinun Achariyapota Gynecologic Oncology Reports . 2020,第2期

机译：eRBB2受体抑制剂在阴道初级标志 - 环细胞腺癌腺癌S310F体细胞α2突变中的含蓄案例：乳腺癌和妇科癌症S310F体细胞α2突变的病例报告及综述文献
4. Singular and combined effects of the isoflavone genistein and the retinoid all-trans-retinoic on multicellular tumor spheroids of the estrogen receptor positive primary breast carcinoma cell line MCF-7. [D] . Nobert, Gayle. 2003

机译：异黄酮金雀异黄素和类视黄醇全反式维甲酸对雌激素受体阳性原发性乳腺癌细胞MCF-7的多细胞肿瘤球体的奇异和联合作用。
5. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets [O] . Sasagu Kurozumi, Mansour Alsaleem, Cíntia J. Monteiro, 2020

机译：可定位的ERBB2突变状态是雌激素受体阳性逆行预后的独立标志ERBB2未扩增的原代小叶乳腺癌：公共数据集的硅分析中的回顾
6. An application of ERBB2 receptor inhibitors in a rare case of S310F somatic ERBB2 mutation of primary signet-ring cell adenocarcinoma of vagina: A case report and review literature of S310F somatic ERBB2 mutation in breast and gynecologic cancers [O] . June Y. Hou, Jason D. Wright, Vuthinun Achariyapota 2020

机译：eRBB2受体抑制剂在阴道初级标志 - 环细胞腺癌腺癌S310F体细胞α2突变中的含蓄案例：乳腺癌和妇科癌症S310F体细胞α2突变的病例报告及综述文献

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets

著录项

引文网络

相似文献

相关主题

期刊订阅